Friday, July 1, 2011
Cancer Journal: Latest cancer research Blocking key cell component could make 'smart drugs' effective for many cancer patients | ecancermedicalscience
AUSTRALIAN scientists have worked out a way of weakening lung cancer, the most deadly form of the disease in the country.
Researchers at the Lowy Cancer Research Centre have found people with lung cancer are loaded with high levels of a protein that is resistant to chemotherapy.
More than 9000 Australians are diagnosed with lung cancer each year and the disease's resistance makes it tricky to treat.
But researchers at the University of NSW centre have developed a gene silencing technique that can switch off the resilient protein cells, making the cancer more sensitive to chemotherapy.
The next step is finding a way to deliver this treatment to the tumour without the body rejecting it, said Professor Maria Kavallaris.
"If you just put it into an animal it would just get excreted straight away," Prof Kavallaris told AAP.
Using existing data from a large clinical trial, the study zeroed in on women with a history of non-melanoma skin cancer, as people with this generally non-fatal disease are more likely to develop the more lethal illness — melanoma. The researchers found that women who once had non-melanoma and took the calcium-vitamin D combination developed 57 percent fewer melanomas than women with similar histories who were not given the supplements. Non-melanoma skin cancers, such as basal cell or squamous cell cancers, are the most common forms of skin cancer.
"In preventive medicine, we want to target people most at risk for the disease," said dermatologist Jean Tang, MD, PhD, lead author of the study. "If you previously had a non-melanoma skin cancer, calcium plus vitamin D might reduce your risk of the more deadly melanoma."
Tang added a note of caution. The study found that a daily dose of 1,000 mg calcium plus 400 IU of vitamin D doesn't provide skin cancer protection for everybody. Women without a history of non-melanoma skin cancer who took the supplements did not see any reduction of risk compared with their placebo-group counterparts, according to the research.
The study will be published online on June 27 in the Journal of Clinical Oncology.
Vitamin D is well-known for its role in bone growth, but it also affects non-skeletal cells. In many parts of the body, including the skin, vitamin D controls how quickly cells replicate, a process that often goes awry in cancer. Reports from various institutions have suggested that vitamin D is associated with lower risks of colon, breast, prostate and other cancers. Nonetheless, the Institute of Medicine published a report last November saying that more research was needed on vitamin D and calcium, as the evidence was insufficient to prove their having a benefit for conditions other than bone health.
This study is the second to look at the effect of vitamin D supplementation on cancer risk with a randomized, controlled trial.
|Cancer Discovery provides a unique forum for paradigm-changing, broad-interest original research, reviews, Research Watch journal summaries, and insightful perspectives in addition to rapid, noteworthy, cancer-specific news. Currently, these types of features appear in disparate publications. This journal is the first source scientists will go to for critical information in cancer science and medicine — in a compact format.|
Tuesday, May 24, 2011
Researchers at the Lowy Cancer Research Centre have found people with lung cancer are loaded with high levels of a protein that is resistant to chemotherapy.More than 9000 Australians are diagnosed with lung cancer each year and the disease's resistance makes it tricky to treat.But researchers at the University of NSW centre have developed a gene silencing technique that can switch off the resilient protein cells, making the cancer more sensitive to chemotherapy.The next step is finding a way to deliver this treatment to the tumour without the body rejecting it, said Professor Maria Kavallaris.Read more: http://www.news.com.au/breaking-news/scientists-can-weaken-lung-cancer/story-e6frfku0-1226054184725#ixzz1NKkuU3tI
Saturday, May 21, 2011
ScienceDaily (May 19, 2011) — A primary reason that head and neck cancer treatments fail is the tumor cells become resistant to chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive Cancer Center have found that a compound derived from the Indian spice curcumin can help cells overcome that resistance.
4 May, 2011
Scientists at Children’s Cancer Institute Australia (CCIA) are developing a new therapy for non-small lung cancer, one of the most lethal types of cancer.
In a twist of fate, scientists looking for a new treatment approach to childhood cancer solid tumours found that this new approach was effective in targeting solid tumours in lung cancer.
The current prognosis for patients with advanced non-small cell lung cancer in Australia is dismal, as tumours often become resistant to conventional drug therapy.
Promising results to be presented at the Australasian Gene Therapy Society meeting in Melbourne suggest that the therapy has the potential to offer new hope to lung cancer patients in Australia and globally.